New EORTC studies opened in 2011
22 Dec 2011
EORTC trial 26091
Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial.
Target Accrual: 144 patients
Study Coordinator:
- Martin J. Van den Bent – Erasmus University Medical Center, Rotterdam
EORTC trial 58081
Translational research – observational study for identification of new possible prognostic factors and future therapeutic targets in children with acute lymphoblastic leukemia (ALL)
Target Accrual: 800 patients
Study Coordinator:
- Helene Cave, Hôpital Robert Debre (AP-HP), Paris
EORTC trial 62091 – TRUSTS
A phase IIb/III multicenter study comparing the efficacy of Trabectedin administered as a 3-hour or 24 hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma
Target Accrual: 370 patients
Study Coordinator:
- Binh Bui-Nguyen – Institut Bergonie, Bordeaux
EORTC trial 08092 – MAPPING
Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy
Target Accrual: 587 patients
Study Coordinator:
- Mary O’Brien – Royal Marsden Hospital, Sutton
EORTC trial 58LAE (Late Adverse Events)
Assessment of the long term outcome of childhood ALL patients enrolled in EORTC CLG trials between 1971 and 1998
Target Accrual: 3138 patients
Study Coordinator:
- Caroline Piette – Centre Hospitalier Regional De La Citadelle, Liege
EORTC trial 26101
Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma
Target Accrual: 249 patients
Study Coordinator:
- Wolfgang Wick – UniversitaetsKlinikum Heidelberg – Kopfklinik, Heidelberg
EORTC studies soon to be opened (in regulatory process)
EORTC trial 06083 – HOVON 100 ALL
Clofarabine added to prephase and consolidation therapy in acute lymphoblastic leukemia in adults. A prospective randomized trial
Target Accrual: – patients
Study Coordinator:
- Jean-Pierre Marie – Hopital Saint Antoine AP-HP, Paris
EORTC trial 21082
Progression free survival (PFS) comparison between suberoylanilide hydroxamic acid (SAHA, Vorinostat TM) in combination with bortezomib (Velcade TM) and SAHA alone in refractory or recurrent advanced CTCL. A randomized study.
Target Accrual: 189 patients
Study Coordinator:
- Pablo Luis Ortiz-Romero – Hospital Universitario, Madrid
EORTC trial 22055 – 08053
Phase III study comparing post-operative conformal radiotherapy to no post-operative radiotherapy in patients with completely resected non-small cell lung cancer and mediastinal N2 involvement – LUNG-ART
Target Accrual: 700 patients
Study Coordinator:
- Cecile Le Pechoux – Institut Gustave Roussy, Villejuif
EORTC trial 40084-22084
A phase III trial evaluating both Erlotinib and Chemoradiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma
Target Accrual: 950 patients
Study Coordinator:
- Jean-Luc Van Laethem – Hospital Universitaire Erasme, Brussels
EORTC trial 55092
Phase IB-II, open label, multicentre feasibility study of Pazopanib in combination with Paclitaxel and Carboplatin in patients with platinum-refractory/resistant ovarian, fallopian tube or peritoneal carcinoma
Target Accrual: 36 patients
Study Coordinator:
- Ignace Vergote – U.Z. Gasthuisberg, Leuven
EORTC trial 62092-22092
A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with Retroperitoneal sarcomas (RPS)
Target Accrual: 256 patients
Study Coordinator:
- Sylvie Bonvalot – Institut Gustave Roussy, Villejuif
EORTC trial 65091 – 06093
Empirical versus pre-emptive antifungal therapy in patients with haematological malignancies. A therapeutic open label phase III strategy study of the EORTC Infectious Diseases and Leukemia Groups
Target Accrual: 556 patients
Study Coordinator:
- Peter Donnelly – Radboud University Nijmegen Medical Centre, Nijmegen
EORTC trial 90101 – CREATE
Cross-tumoral Phase 2 clinical trial exploring crizotinib (PF-02341066) in patients with advanced tumors induced by causal alterations of ALK and/or MET (“CREATE”)
Target Accrual: 582 patients
Study Coordinator:
- Patrick Schoeffski – U.Z. Gasthuisberg, Leuven
John Bean
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023